Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 18/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1090077 | 0.87 | SMO (0.72) | SMOMEN1KMT2A | |
| SCHEMBL1102304 | 0.84 | NR1H2 (0.54) | SMOMEN1GFERKMT2A | |
| SCHEMBL4183815 | 0.84 | SMO (0.74) | SMOMEN1GFERKMT2A | |
| SCHEMBL1102297 | 0.84 | SMO (0.74) | SMOMEN1GFERKMT2A | |
| SCHEMBL10193554 | 0.83 | SMO (0.52) | SMOCDK1IGF1RFGFR1BRAF | |
| SCHEMBL3700116 | 0.76 | SMO (0.66) | SMO | |
| SCHEMBL3700114 | 0.76 | SMO (0.66) | SMO | |
| SCHEMBL2272698 | 0.75 | SMO (0.59) | SMOMEN1GFERKMT2A | |
| SCHEMBL4171980 | 0.75 | SMO (0.69) | SMO | |
| SCHEMBL1090000 | 0.75 | SMO (0.67) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2170866-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | SMO 520/4885MEN1 471/4885GFER 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.